Cytiva And WhiteLab Genomics Team Up To Use AI To Accelerate Cell Line Development

Collaboration will help reduce stable cell line development timelines in AAV genomic medicine development and ultimately also shorten development timeline to clinic

Cytiva, a Danaher company and a global leader in the life sciences industry, and WhiteLab Genomics, a techbio company specializing in artificial intelligence for genomic medicine research and development, announced a collaboration to accelerate the development of next-generation genomic medicines.

As part of this collaboration, WhiteLab Genomics will use its proprietary AI-powered technology to optimize and accelerate stable cell line development. By analyzing complex biological data with advanced data analysis, WhiteLab’s platform will help improve the stable cell line clone selection process, all through computer simulations.

“Through the integration of AI-driven predictive modeling into AAV development workflows, we aim to reduce development timelines and associated costs by up to 70%,” said David Del Bourgo, CEO and Co-Founder of WhiteLab Genomics. “This is a significant impact when the total cost of bringing a genomic medicine to market can approach nearly USD 2 billion, enabling a more efficient, scalable path to clinical and commercial readiness in genomic medicine.”

Combined with Cytiva’s expertise in stable cell lines for AAV production, the collaboration aims to benefit researchers in advanced therapies and their patients.

“Genomic medicines will be critical to address some of the world’s greatest health challenges. By combining Cytiva’s experience with WhiteLab’s technology, we intend to help manufacturers reach clinical and regulatory milestones faster benefiting patients around the world,” said Emmanuel Abate, President of Genomic Medicine, Cytiva

Learn more about optimizing your cell line strategy for better viral vector production at https://cytiva.link/BPI-CLD-Strategy.

About WhiteLab Genomics
WhiteLab Genomics, a pioneer in the accelerated development of genomic medicines, sits at the intersection of artificial intelligence and biology. Founded in 2019 and supported by Y-Combinator, the company is establishing itself as a key player in genomic medicine innovation. Its proprietary AI technology enables the analysis of complex biological data and the in silico design of optimized therapeutic candidates, thus reducing development time, costs, and associated risks. WhiteLab collaborates with major pharmaceutical companies (such as Sanofi), leading academic institutions, and innovative biotech companies. WhiteLab is a member of the prestigious French Tech 2030 program and recently joined Bayer Co.Lab in Cambridge (USA) as well as the Technology Network of Ginkgo Bioworks. For more information, visit White Lab Genomics (https://whitelabgx.com/).

About Cytiva
At Cytiva, our mission is to advance and accelerate the development of therapeutics. With 15 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers. For more information, visit Cytiva.com.

Cytiva is proud to be part of Danaher. For more information, visit www.Danaher.com to learn more about Danaher, a leading life sciences and diagnostics innovator committed to accelerating the power of science and technology to improve human health.